trending Market Intelligence /marketintelligence/en/news-insights/trending/b9y5hlgvxphknhxzucllng2 content esgSubNav
In This List

Stellar Biotechnologies prices $5.5M offering

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Stellar Biotechnologies prices $5.5M offering

Stellar Biotechnologies Inc. priced a public offering of 2,075,472 units at $2.65 apiece to raise about $5.5 million in proceeds.

The funds are expected to be used for general corporate purposes, which may include research and development activities, capital expenditures, and working capital.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the Los Angeles-based company's offering, which is expected to close by May 15.

Each unit comprises 1 common share and 1 warrant to buy an additional stock for $2.65 each.